• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
158102 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
# h: [+ l% {: ]( D+ O3 k6 o" y
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
" v7 o6 X9 V9 ?+ D; b
$ ]; {! d; h5 T1 D+ n. B; `: d) l+ |- m3 d" S
Sub-category:2 j+ g% a" o/ ^6 k
Molecular Targets ) d; k. I1 x* [9 C8 c3 z; {
1 N4 J: q, {  q5 h

9 Z  m/ U8 N. E# _0 M7 U9 m9 H) JCategory:
: c- |7 j8 x' q5 _. Z, aTumor Biology " X6 G0 _9 n' g8 N. s9 u

5 r6 K- B% M  [4 e* u5 |" S9 g/ o" k( S
: O, V) I- ~, l: AMeeting:+ y% i. w9 h# U8 m, Q
2011 ASCO Annual Meeting
+ ^4 L7 V# m- P' g; W8 W$ H1 O) d  P
& i2 t- I. U( Z
+ v. t# H' [1 ASession Type and Session Title:. T$ O9 R: b% u0 m9 i$ T
Poster Discussion Session, Tumor Biology ' e3 y6 g1 b5 ~+ Y

# y6 a% Q5 t$ Z$ e7 z
! `9 t5 S- Z( P% ], \2 @Abstract No:
% X* ^8 ]3 B" G4 g. C10517
' K8 f) y2 J9 @$ T( E" z+ z; i  B4 o" t9 A) l* j$ c4 o! N$ I
( ~$ m2 R+ j+ z& _* U
Citation:
1 Y: }9 j6 q. \- bJ Clin Oncol 29: 2011 (suppl; abstr 10517) 3 P. [! L# I7 i( F) I/ U
5 b% u/ L$ L7 F- l

" i6 U6 D$ e3 s5 G% o! mAuthor(s):; ]4 f' d3 _7 P6 {" a
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , Z$ F% e8 S" }- a, x! a

7 C) A$ R2 G+ L2 s: n" F
1 N& _$ l2 c0 T2 k
) i- |$ F& [" Y" dAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
$ d' T2 L/ J" b* P
7 E4 S- l; T' S% f1 f, @$ LAbstract Disclosures
% W) B. ?' W& [6 I/ Y. E& A
; m. ^5 O) T; s! S% eAbstract:3 f& h+ L$ c& y$ B0 r; m

' W, p8 h; w) g; w; G- D/ L- F7 X+ M
  k6 h' H( X1 C5 I+ x9 p# c+ W) u+ oBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.$ W4 N7 _6 I5 P3 D% |# A6 I

9 ~: w9 b1 {) L ! ?# q; `3 f' ~$ {$ V. Q( w" K
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 & B* W8 E9 \1 E2 |3 `+ Z
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

/ O5 Y0 |- w+ D. a7 [1 F化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 : K6 ]5 Z& u3 O3 R4 \6 @3 T
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。! B$ \8 P$ `3 t1 F* W
ALK一个指标医院要900多 ...
1 t+ C5 n$ E; `1 W' q/ b# b- B
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
- t! s0 J: {3 Z8 T3 ]
! J& N) x* w2 F, G" }9 ^8 E6 W现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表